OMEROS CORP
OMEROS CORP (OMER): 9 pipeline candidates · ~29 mo cash runway · 8 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
29.4 months
25% dilution
Lead: Approved
9 candidates
N/A
0 buys · 3 sells (180d)
A transparent, data-derived signal for OMEROS CORPacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$707.1M
Cash
$1.9M
Quarterly Burn
$14.5M
Runway
29.4 mo
Revenue
$9.9M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| narsoplimab | Phase 2 |
| oms1029 | Phase 1 |
| oms527 | Phase 1 |
| oms721 | Phase 3 |
| oms906 | Phase 2 |
| oms906 study | Phase 2 |
| oncotox-aml | Preclinical |
| yartemlea | Approved |
| zaltenibart | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
159
Total value held
$306.9M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 5,966,518 | $63.0M |
| blackrock, inc. | 5,309,626 | $56.1M |
| state street corp | 1,919,575 | $20.3M |
| stifel financial corp | 1,831,585 | $19.3M |
| geode capital management, llc | 1,752,323 | $18.5M |
| susquehanna international group, llp | 1,404,130 | $14.8M |
| vanguard portfolio management llc | 718,675 | $7.6M |
| citadel advisors llc | 714,148 | $7.5M |
| charles schwab investment management inc | 582,512 | $6.2M |
| bank of montreal /can/ | 568,426 | $6.0M |
Showing top 10 of 159 institutional holders of OMEROS CORP. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in OMEROS CORP's pipeline?
OMEROS CORP (OMER) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is OMEROS CORP's lead drug candidate?
OMEROS CORP's most advanced tracked candidate is narsoplimab (Phase 2) for Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA).
What is OMEROS CORP's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, OMEROS CORP has approximately 29.4 months of cash runway.
What is OMEROS CORP's market capitalization?
OMEROS CORP's market capitalization is approximately $707.1M.
Who is the CEO of OMEROS CORP?
Dr. Gregory A. Demopulos M.D. is the chief executive officer of OMEROS CORP (OMER).
Get the full picture on OMEROS CORP
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.